{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T20:09:58Z","timestamp":1779480598189,"version":"3.53.1"},"reference-count":214,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T00:00:00Z","timestamp":1779408000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T00:00:00Z","timestamp":1779408000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Oncol Rep"],"DOI":"10.1007\/s11912-026-01792-5","type":"journal-article","created":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T07:41:02Z","timestamp":1779435662000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Advancing Systemic Treatment beyond First Line for Advanced Hepatocellular Carcinoma"],"prefix":"10.1007","volume":"28","author":[{"given":"Piotr T.","family":"Wysocki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulina","family":"Chmiel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacek","family":"Jassem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leszek","family":"Kraj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,22]]},"reference":[{"key":"1792_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229\u201363. https:\/\/doi.org\/10.3322\/caac.21834.","journal-title":"CA Cancer J Clin"},{"key":"1792_CR2","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/j.jhep.2025.10.020","volume":"84","author":"M Reig","year":"2026","unstructured":"Reig M, et al. BCLC strategy for prognosis prediction and treatment recommendations: the 2026 update. J Hepatol. 2026;84:631\u201354. https:\/\/doi.org\/10.1016\/j.jhep.2025.10.020.","journal-title":"J Hepatol"},{"key":"1792_CR3","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12061663","author":"JJG Marin","year":"2020","unstructured":"Marin JJG, et al. Molecular bases of drug resistance in hepatocellular carcinoma. Cancers (Basel). 2020. https:\/\/doi.org\/10.3390\/cancers12061663.","journal-title":"Cancers (Basel)"},{"key":"1792_CR4","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1038\/s43018-022-00357-2","volume":"3","author":"JM Llovet","year":"2022","unstructured":"Llovet JM, et al. Molecular pathogenesis and systemic therapies for hepatocellular carcinoma. Nat Cancer. 2022;3:386\u2013401. https:\/\/doi.org\/10.1038\/s43018-022-00357-2.","journal-title":"Nat Cancer"},{"key":"1792_CR5","doi-asserted-by":"publisher","first-page":"2490","DOI":"10.1016\/j.cell.2026.03.001","volume":"189","author":"JM Llovet","year":"2026","unstructured":"Llovet JM, et al. Hallmarks of liver cancer: therapeutic implications. Cell. 2026;189:2490\u2013514. https:\/\/doi.org\/10.1016\/j.cell.2026.03.001.","journal-title":"Cell"},{"key":"1792_CR6","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1056\/NEJMoa0708857","volume":"359","author":"JM Llovet","year":"2008","unstructured":"Llovet JM, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378\u201390. https:\/\/doi.org\/10.1056\/NEJMoa0708857.","journal-title":"N Engl J Med"},{"key":"1792_CR7","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/s1470-2045(08)70285-7","volume":"10","author":"AL Cheng","year":"2009","unstructured":"Cheng AL, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10:25\u201334. https:\/\/doi.org\/10.1016\/s1470-2045(08)70285-7.","journal-title":"Lancet Oncol"},{"key":"1792_CR8","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","volume":"391","author":"M Kudo","year":"2018","unstructured":"Kudo M, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018;391:1163\u201373. https:\/\/doi.org\/10.1016\/S0140-6736(18)30207-1.","journal-title":"Lancet"},{"key":"1792_CR9","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1159\/000515305","volume":"10","author":"C-L Hsu","year":"2021","unstructured":"Hsu C-L, et al. Exploring markers of exhausted CD8 T Cells to predict response to immune checkpoint inhibitor therapy for hepatocellular carcinoma. Liver Cancer. 2021;10:346\u201359. https:\/\/doi.org\/10.1159\/000515305.","journal-title":"Liver Cancer"},{"key":"1792_CR10","doi-asserted-by":"publisher","first-page":"35056","DOI":"10.1038\/srep35056","volume":"6","author":"J-F Tu","year":"2016","unstructured":"Tu J-F, et al. Regulatory T cells, especially ICOS+ FOXP3+ regulatory T cells, are increased in the hepatocellular carcinoma microenvironment and predict reduced survival. Sci Rep. 2016;6:35056. https:\/\/doi.org\/10.1038\/srep35056.","journal-title":"Sci Rep"},{"key":"1792_CR11","doi-asserted-by":"publisher","first-page":"2328","DOI":"10.1053\/j.gastro.2007.03.102","volume":"132","author":"J Fu","year":"2007","unstructured":"Fu J, et al. Increased regulatory T Cells correlate with CD8 T-Cell impairment and poor survival in Hepatocellular Carcinoma patients. Gastroenterology. 2007;132:2328\u201339. https:\/\/doi.org\/10.1053\/j.gastro.2007.03.102.","journal-title":"Gastroenterology"},{"key":"1792_CR12","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","volume":"382","author":"RS Finn","year":"2020","unstructured":"Finn RS, et al. Atezolizumab plus Bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382:1894\u2013905. https:\/\/doi.org\/10.1056\/NEJMoa1915745.","journal-title":"N Engl J Med"},{"key":"1792_CR13","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1016\/j.jhep.2021.11.030","volume":"76","author":"A-L Cheng","year":"2022","unstructured":"Cheng A-L, et al. Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma. J Hepatol. 2022;76:862\u201373. https:\/\/doi.org\/10.1016\/j.jhep.2021.11.030.","journal-title":"J Hepatol"},{"key":"1792_CR14","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1016\/S1470-2045(21)00252-7","volume":"22","author":"Z Ren","year":"2021","unstructured":"Ren Z, et al. Sintilimab plus a Bevacizumab biosimilar (IBI305) versus Sorafenib in unresectable Hepatocellular Carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study. Lancet Oncol. 2021;22:977\u201390. https:\/\/doi.org\/10.1016\/S1470-2045(21)00252-7.","journal-title":"Lancet Oncol"},{"key":"1792_CR15","doi-asserted-by":"publisher","first-page":"EVIDoa2100070","DOI":"10.1056\/EVIDoa2100070","volume":"1","author":"GK Abou-Alfa","year":"2022","unstructured":"Abou-Alfa GK, et al. Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma. NEJM Evid. 2022;1:EVIDoa2100070. https:\/\/doi.org\/10.1056\/EVIDoa2100070.","journal-title":"NEJM Evid"},{"key":"1792_CR16","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1016\/j.annonc.2024.02.005","volume":"35","author":"B Sangro","year":"2024","unstructured":"Sangro B, et al. Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. Ann Oncol. 2024;35:448\u201357. https:\/\/doi.org\/10.1016\/j.annonc.2024.02.005.","journal-title":"Ann Oncol"},{"key":"1792_CR17","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1001\/jamaoncol.2023.4003","volume":"9","author":"S Qin","year":"2023","unstructured":"Qin S, et al. Tislelizumab vs Sorafenib as first-line treatment for unresectable hepatocellular carcinoma: A Phase 3 randomized clinical trial. JAMA Oncol. 2023;9:1651\u20139. https:\/\/doi.org\/10.1001\/jamaoncol.2023.4003.","journal-title":"JAMA Oncol"},{"key":"1792_CR18","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1016\/S0140-6736(25)00403-9","volume":"405","author":"T Yau","year":"2025","unstructured":"Yau T, et al. Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial. Lancet. 2025;405:1851\u201364. https:\/\/doi.org\/10.1016\/S0140-6736(25)00403-9.","journal-title":"Lancet"},{"key":"1792_CR19","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1016\/S1470-2045(22)00326-6","volume":"23","author":"RK Kelley","year":"2022","unstructured":"Kelley RK, et al. Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2022;23:995\u20131008. https:\/\/doi.org\/10.1016\/S1470-2045(22)00326-6.","journal-title":"Lancet Oncol"},{"key":"1792_CR20","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1016\/S1470-2045(23)00469-2","volume":"24","author":"JM Llovet","year":"2023","unstructured":"Llovet JM, et al. Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial. Lancet Oncol. 2023;24:1399\u2013410. https:\/\/doi.org\/10.1016\/S1470-2045(23)00469-2.","journal-title":"Lancet Oncol"},{"key":"1792_CR21","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1016\/S0140-6736(23)00961-3","volume":"402","author":"S Qin","year":"2023","unstructured":"Qin S, et al. Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study. Lancet. 2023;402:1133\u201346. https:\/\/doi.org\/10.1016\/S0140-6736(23)00961-3.","journal-title":"Lancet"},{"key":"1792_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2025.02.006","author":"A Vogel","year":"2025","unstructured":"Vogel A, et al. Hepatocellular carcinoma: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2025. https:\/\/doi.org\/10.1016\/j.annonc.2025.02.006.","journal-title":"Ann Oncol"},{"key":"1792_CR23","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.1200\/jco.23.02745","volume":"42","author":"JD Gordan","year":"2024","unstructured":"Gordan JD, et al. Systemic therapy for advanced hepatocellular carcinoma: ASCO guideline update. J Clin Oncol. 2024;42:1830\u201350. https:\/\/doi.org\/10.1200\/jco.23.02745.","journal-title":"J Clin Oncol"},{"key":"1792_CR24","unstructured":"National Comprehensive Cancer Network. Hepatocellular Carcinoma (Version 4.2024), <https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/hcc.pdf> (2024)"},{"key":"1792_CR25","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1001\/jamaoncol.2023.2677","volume":"10","author":"S Cappuyns","year":"2024","unstructured":"Cappuyns S, Corbett V, Yarchoan M, Finn RS, Llovet JM. Critical appraisal of guideline recommendations on systemic therapies for advanced hepatocellular carcinoma: a review. JAMA Oncol. 2024;10:395\u2013404. https:\/\/doi.org\/10.1001\/jamaoncol.2023.2677.","journal-title":"JAMA Oncol"},{"key":"1792_CR26","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.jhep.2024.08.028","volume":"82","author":"B Sangro","year":"2025","unstructured":"Sangro B, et al. EASL clinical practice guidelines on the management of hepatocellular carcinoma. J Hepatol. 2025;82:315\u201374. https:\/\/doi.org\/10.1016\/j.jhep.2024.08.028.","journal-title":"J Hepatol"},{"key":"1792_CR27","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.canlet.2019.03.037","volume":"453","author":"S Liu","year":"2019","unstructured":"Liu S, et al. Preclinical comparison of regorafenib and sorafenib efficacy for hepatocellular carcinoma using multimodality molecular imaging. Cancer Lett. 2019;453:74\u201383. https:\/\/doi.org\/10.1016\/j.canlet.2019.03.037.","journal-title":"Cancer Lett"},{"key":"1792_CR28","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/S0140-6736(16)32453-9","volume":"389","author":"J Bruix","year":"2017","unstructured":"Bruix J, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;389:56\u201366. https:\/\/doi.org\/10.1016\/S0140-6736(16)32453-9.","journal-title":"Lancet"},{"key":"1792_CR29","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1200\/JCO.2020.38.4_suppl.499","volume":"38","author":"PJ Ross","year":"2020","unstructured":"Ross PJ, et al. Real-world experience of regorafenib in patients with hepatocellular carcinoma: A multicenter United Kingdom study. J Clin Oncol. 2020;38:499\u2013499. https:\/\/doi.org\/10.1200\/JCO.2020.38.4_suppl.499.","journal-title":"J Clin Oncol"},{"key":"1792_CR30","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1002\/hep4.1523","volume":"4","author":"WM Choi","year":"2020","unstructured":"Choi WM, et al. Regorafenib versus nivolumab after sorafenib failure: real-world data in patients with hepatocellular carcinoma. Hepatol Commun. 2020;4:1073\u201386. https:\/\/doi.org\/10.1002\/hep4.1523.","journal-title":"Hepatol Commun"},{"key":"1792_CR31","doi-asserted-by":"publisher","first-page":"2263","DOI":"10.1111\/liv.14496","volume":"40","author":"C Yoo","year":"2020","unstructured":"Yoo C, et al. Regorafenib in previously treated advanced hepatocellular carcinoma: Impact of prior immunotherapy and adverse events. Liver Int. 2020;40:2263\u201371. https:\/\/doi.org\/10.1111\/liv.14496.","journal-title":"Liver Int"},{"key":"1792_CR32","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s12876-023-02661-2","volume":"23","author":"Q Zhu","year":"2023","unstructured":"Zhu Q, et al. Real-world systemic sequential therapy with regorafenib for recurrent hepatocellular carcinoma: analysis of 93 cases from a single center. BMC Gastroenterol. 2023;23:28. https:\/\/doi.org\/10.1186\/s12876-023-02661-2.","journal-title":"BMC Gastroenterol"},{"key":"1792_CR33","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1007\/s10637-019-00801-8","volume":"38","author":"S Ogasawara","year":"2020","unstructured":"Ogasawara S, et al. Sequential therapy with sorafenib and regorafenib for advanced hepatocellular carcinoma: a multicenter retrospective study in Japan. Invest New Drugs. 2020;38:172\u201380. https:\/\/doi.org\/10.1007\/s10637-019-00801-8.","journal-title":"Invest New Drugs"},{"key":"1792_CR34","doi-asserted-by":"publisher","unstructured":"Wang W et al. (2019) Sorafenib-Regorafenib sequential therapy in Japanese patients with unresectable hepatocellular carcinoma-relative dose intensity and Post-Regorafenib therapies in real world practice. Cancers (Basel) 11. https:\/\/doi.org\/10.3390\/cancers11101517","DOI":"10.3390\/cancers11101517"},{"key":"1792_CR35","doi-asserted-by":"publisher","unstructured":"Kim YJ et al. (2024) Regorafenib for hepatocellular carcinoma in real-world practice (REFINE): a prospective, observational study. Liver Cancer 1\u201317. https:\/\/doi.org\/10.1159\/000542285","DOI":"10.1159\/000542285"},{"key":"1792_CR36","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1007\/s12032-020-01350-4","volume":"37","author":"R Fu","year":"2020","unstructured":"Fu R, Jiang S, Li J, Chen H, Zhang X. Activation of the HGF\/c-MET axis promotes lenvatinib resistance in hepatocellular carcinoma cells with high c-MET expression. Med Oncol. 2020;37:24. https:\/\/doi.org\/10.1007\/s12032-020-01350-4.","journal-title":"Med Oncol"},{"key":"1792_CR37","first-page":"896","volume":"15","author":"Y Ma","year":"2023","unstructured":"Ma Y, Liu X, Tang X. ETS-1\/c-Met drives resistance to sorafenib in hepatocellular carcinoma. Am J Transl Res. 2023;15:896\u2013913.","journal-title":"Am J Transl Res"},{"key":"1792_CR38","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1111\/cas.12891","volume":"107","author":"Z Firtina Karagonlar","year":"2016","unstructured":"Firtina Karagonlar Z, Koc D, Iscan E, Erdal E, Atabey N. Elevated hepatocyte growth factor expression as an autocrine c-Met activation mechanism in acquired resistance to sorafenib in hepatocellular carcinoma cells. Cancer Sci. 2016;107:407\u201316. https:\/\/doi.org\/10.1111\/cas.12891.","journal-title":"Cancer Sci"},{"key":"1792_CR39","doi-asserted-by":"publisher","first-page":"2959","DOI":"10.1158\/1078-0432.Ccr-13-2620","volume":"20","author":"Q Xiang","year":"2014","unstructured":"Xiang Q, et al. Cabozantinib suppresses tumor growth and metastasis in hepatocellular carcinoma by a dual blockade of VEGFR2 and MET. Clin Cancer Res. 2014;20:2959\u201370. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-13-2620.","journal-title":"Clin Cancer Res"},{"key":"1792_CR40","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1093\/carcin\/bgt372","volume":"35","author":"HJ Lee","year":"2014","unstructured":"Lee HJ, Jeng YM, Chen YL, Chung L, Yuan RH. Gas6\/Axl pathway promotes tumor invasion through the transcriptional activation of Slug in hepatocellular carcinoma. Carcinogenesis. 2014;35:769\u201375. https:\/\/doi.org\/10.1093\/carcin\/bgt372.","journal-title":"Carcinogenesis"},{"key":"1792_CR41","doi-asserted-by":"publisher","first-page":"2687","DOI":"10.1038\/onc.2015.343","volume":"35","author":"L Zhou","year":"2016","unstructured":"Zhou L, et al. Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma. Oncogene. 2016;35:2687\u201397. https:\/\/doi.org\/10.1038\/onc.2015.343.","journal-title":"Oncogene"},{"key":"1792_CR42","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1038\/s41419-024-06493-0","volume":"15","author":"Y Xie","year":"2024","unstructured":"Xie Y, et al. Targeting AXL induces tumor-intrinsic immunogenic response in tyrosine kinase inhibitor-resistant liver cancer. Cell Death Dis. 2024;15:110. https:\/\/doi.org\/10.1038\/s41419-024-06493-0.","journal-title":"Cell Death Dis"},{"key":"1792_CR43","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1038\/s41416-018-0373-6","volume":"120","author":"DJ Pinato","year":"2019","unstructured":"Pinato DJ, et al. Integrated analysis of multiple receptor tyrosine kinases identifies Axl as a therapeutic target and mediator of resistance to sorafenib in hepatocellular carcinoma. Br J Cancer. 2019;120:512\u201321. https:\/\/doi.org\/10.1038\/s41416-018-0373-6.","journal-title":"Br J Cancer"},{"key":"1792_CR44","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1056\/NEJMoa1717002","volume":"379","author":"GK Abou-Alfa","year":"2018","unstructured":"Abou-Alfa GK, et al. Cabozantinib in patients with advanced and progressing hepatocellular carcinoma. N Engl J Med. 2018;379:54\u201363. https:\/\/doi.org\/10.1056\/NEJMoa1717002.","journal-title":"N Engl J Med"},{"key":"1792_CR45","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.ejca.2022.03.021","volume":"168","author":"N Freemantle","year":"2022","unstructured":"Freemantle N, et al. Quality of life assessment of cabozantinib in patients with advanced hepatocellular carcinoma in the CELESTIAL trial. Eur J Cancer. 2022;168:91\u20138. https:\/\/doi.org\/10.1016\/j.ejca.2022.03.021.","journal-title":"Eur J Cancer"},{"key":"1792_CR46","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2020-000714","author":"RK Kelley","year":"2020","unstructured":"Kelley RK, et al. Second-line cabozantinib after sorafenib treatment for advanced hepatocellular carcinoma: a subgroup analysis of the phase 3 CELESTIAL trial. ESMO Open. 2020. https:\/\/doi.org\/10.1136\/esmoopen-2020-000714.","journal-title":"ESMO Open"},{"key":"1792_CR47","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1111\/hepr.13876","volume":"53","author":"N Kato","year":"2023","unstructured":"Kato N, et al. Cabozantinib in Japanese patients with advanced hepatocellular carcinoma: Final results of a multicenter phase II study. Hepatol Res. 2023;53:409\u201316. https:\/\/doi.org\/10.1111\/hepr.13876.","journal-title":"Hepatol Res"},{"key":"1792_CR48","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1159\/000515551","volume":"10","author":"F Tovoli","year":"2021","unstructured":"Tovoli F, et al. Real-life clinical data of Cabozantinib for unresectable hepatocellular carcinoma. Liver Cancer. 2021;10:370\u20139. https:\/\/doi.org\/10.1159\/000515551.","journal-title":"Liver Cancer"},{"key":"1792_CR49","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1007\/s40801-023-00379-x","volume":"10","author":"H Kanzaki","year":"2023","unstructured":"Kanzaki H, et al. Cabozantinib for advanced hepatocellular carcinoma in the latest real-world practice: a multicenter retrospective analysis. Drugs Real World Outcomes. 2023;10:513\u201320. https:\/\/doi.org\/10.1007\/s40801-023-00379-x.","journal-title":"Drugs Real World Outcomes"},{"key":"1792_CR50","doi-asserted-by":"publisher","first-page":"175883592210979","DOI":"10.1177\/17588359221097934","volume":"14","author":"YH Bang","year":"2022","unstructured":"Bang YH, et al. Real-world efficacy and safety of cabozantinib in Korean patients with advanced hepatocellular carcinoma: a multicenter retrospective analysis. Ther Adv Med Oncol. 2022;14:17588359221097934. https:\/\/doi.org\/10.1177\/17588359221097934.","journal-title":"Ther Adv Med Oncol"},{"key":"1792_CR51","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1159\/000515490","volume":"10","author":"F Finkelmeier","year":"2021","unstructured":"Finkelmeier F, et al. Cabozantinib in advanced hepatocellular carcinoma: efficacy and safety data from an international multicenter real-life Cohort. Liver Cancer. 2021;10:360\u20139. https:\/\/doi.org\/10.1159\/000515490.","journal-title":"Liver Cancer"},{"key":"1792_CR52","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1200\/JCO.2023.41.4_suppl.573","volume":"41","author":"P Merle","year":"2023","unstructured":"Merle P, et al. Cabozantinib (CABO) tolerance and efficacy for patients with advanced hepatocellular carcinoma (HCC) after failure of sorafenib (SOR) in a French population: CLERANCE, a phase 4 trial. J Clin Oncol. 2023;41:573\u2013573. https:\/\/doi.org\/10.1200\/JCO.2023.41.4_suppl.573.","journal-title":"J Clin Oncol"},{"key":"1792_CR53","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1111\/liv.12778","volume":"35","author":"S Maria","year":"2015","unstructured":"Maria S, et al. Expression of pERK and VEGFR-2 in advanced hepatocellular carcinoma and resistance to sorafenib treatment. Liver Int. 2015;35:2001\u20138. https:\/\/doi.org\/10.1111\/liv.12778.","journal-title":"Liver Int"},{"key":"1792_CR54","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1016\/s1470-2045(15)00050-9","volume":"16","author":"AX Zhu","year":"2015","unstructured":"Zhu AX, et al. Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol. 2015;16:859\u201370. https:\/\/doi.org\/10.1016\/s1470-2045(15)00050-9.","journal-title":"Lancet Oncol"},{"key":"1792_CR55","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/s1470-2045(18)30937-9","volume":"20","author":"AX Zhu","year":"2019","unstructured":"Zhu AX, et al. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased \u03b1-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019;20:282\u201396. https:\/\/doi.org\/10.1016\/s1470-2045(18)30937-9.","journal-title":"Lancet Oncol"},{"key":"1792_CR56","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s12876-023-02674-x","volume":"23","author":"N Kanogawa","year":"2023","unstructured":"Kanogawa N, et al. Use of ramucirumab for various treatment lines in real-world practice of patients with advanced hepatocellular carcinoma. BMC Gastroenterol. 2023;23:70. https:\/\/doi.org\/10.1186\/s12876-023-02674-x.","journal-title":"BMC Gastroenterol"},{"key":"1792_CR57","doi-asserted-by":"publisher","first-page":"e938","DOI":"10.1093\/oncolo\/oyac183","volume":"27","author":"RS Finn","year":"2022","unstructured":"Finn RS, et al. Ramucirumab for patients with advanced hepatocellular carcinoma and elevated alpha fetoprotein following Non-Sorafenib systemic therapy: an expansion Cohort of REACH-2. Oncologist. 2022;27:e938\u201348. https:\/\/doi.org\/10.1093\/oncolo\/oyac183.","journal-title":"Oncologist"},{"key":"1792_CR58","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/S2468-1253(21)00109-6","volume":"6","author":"S Qin","year":"2021","unstructured":"Qin S, et al. Apatinib as second-line or later therapy in patients with advanced hepatocellular carcinoma (AHELP): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Gastroenterol Hepatol. 2021;6:559\u201368. https:\/\/doi.org\/10.1016\/S2468-1253(21)00109-6.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"1792_CR59","doi-asserted-by":"publisher","first-page":"3509","DOI":"10.1200\/jco.2012.47.3009","volume":"31","author":"JM Llovet","year":"2013","unstructured":"Llovet JM, et al. Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to Sorafenib or for whom Sorafenib failed: results from the randomized Phase III BRISK-PS Study. J Clin Oncol. 2013;31:3509\u201316. https:\/\/doi.org\/10.1200\/jco.2012.47.3009.","journal-title":"J Clin Oncol"},{"key":"1792_CR60","doi-asserted-by":"publisher","unstructured":"Jefremow A et al. (2020) Beyond the border: the use of lenvatinib in advanced hepatocellular carcinoma after different treatment lines: a retrospective analysis. J Physiol Pharmacol 71. https:\/\/doi.org\/10.26402\/jpp.2020.5.11","DOI":"10.26402\/jpp.2020.5.11"},{"key":"1792_CR61","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1159\/000507022","volume":"9","author":"S Maruta","year":"2020","unstructured":"Maruta S, et al. Potential of Lenvatinib for an expanded indication from the REFLECT trial in patients with advanced hepatocellular carcinoma. Liver Cancer. 2020;9:382\u201396. https:\/\/doi.org\/10.1159\/000507022.","journal-title":"Liver Cancer"},{"key":"1792_CR62","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.18632\/oncotarget.27640","volume":"11","author":"T Tomonari","year":"2020","unstructured":"Tomonari T, et al. Potential use of lenvatinib for patients with unresectable hepatocellular carcinoma including after treatment with sorafenib: Real-world evidence and in vitro assessment via protein phosphorylation array. Oncotarget. 2020;11:2531.","journal-title":"Oncotarget"},{"key":"1792_CR63","doi-asserted-by":"publisher","first-page":"e204564","DOI":"10.1001\/jamaoncol.2020.4564","volume":"6","author":"T Yau","year":"2020","unstructured":"Yau T, et al. Efficacy and safety of Nivolumab plus Ipilimumab in Patients with advanced hepatocellular carcinoma previously treated with Sorafenib: The CheckMate 040 Randomized Clinical Trial. JAMA Oncol. 2020;6:e204564. https:\/\/doi.org\/10.1001\/jamaoncol.2020.4564.","journal-title":"JAMA Oncol"},{"key":"1792_CR64","doi-asserted-by":"publisher","first-page":"2492","DOI":"10.1016\/S0140-6736(17)31046-2","volume":"389","author":"AB El-Khoueiry","year":"2017","unstructured":"El-Khoueiry AB, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1\/2 dose escalation and expansion trial. Lancet. 2017;389:2492\u2013502. https:\/\/doi.org\/10.1016\/S0140-6736(17)31046-2.","journal-title":"Lancet"},{"key":"1792_CR65","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.annonc.2023.12.008","volume":"35","author":"AB El-Khoueiry","year":"2024","unstructured":"El-Khoueiry AB, et al. Nivolumab in Sorafenib-naive and Sorafenib-experienced patients with advanced hepatocellular carcinoma: 5-year follow-up from CheckMate 040. Ann Oncol. 2024;35:381\u201391. https:\/\/doi.org\/10.1016\/j.annonc.2023.12.008.","journal-title":"Ann Oncol"},{"key":"1792_CR66","doi-asserted-by":"publisher","unstructured":"Melero I et al. (2024) Nivolumab plus ipilimumab combination therapy in patients with advanced hepatocellular carcinoma previously treated with sorafenib: 5-year results from CheckMate 040. Ann Oncol. https:\/\/doi.org\/10.1016\/j.annonc.2024.03.005","DOI":"10.1016\/j.annonc.2024.03.005"},{"key":"1792_CR67","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1200\/jco.19.01307","volume":"38","author":"RS Finn","year":"2020","unstructured":"Finn RS, et al. Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: a randomized, double-blind, phase III trial. J Clin Oncol. 2020;38:193\u2013202. https:\/\/doi.org\/10.1200\/jco.19.01307.","journal-title":"J Clin Oncol"},{"key":"1792_CR68","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1200\/JCO.2022.40.4_suppl.383","volume":"40","author":"S Qin","year":"2022","unstructured":"Qin S, et al. Pembrolizumab plus best supportive care versus placebo plus best supportive care as second-line therapy in patients in Asia with advanced hepatocellular carcinoma (HCC): phase 3 KEYNOTE-394 study. J Clin Oncol. 2022;40:383\u2013383. https:\/\/doi.org\/10.1200\/JCO.2022.40.4_suppl.383.","journal-title":"J Clin Oncol"},{"key":"1792_CR69","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1016\/j.dld.2023.03.005","volume":"55","author":"V Haghnejad","year":"2023","unstructured":"Haghnejad V, et al. Atezolizumab plus Bevacizumab in advanced hepatocellular carcinoma after treatment failure with multikinase inhibitors. Dig Liver Dis. 2023;55:938\u201344. https:\/\/doi.org\/10.1016\/j.dld.2023.03.005.","journal-title":"Dig Liver Dis"},{"key":"1792_CR70","doi-asserted-by":"publisher","first-page":"e1464","DOI":"10.1002\/cnr2.1464","volume":"5","author":"A Hiraoka","year":"2022","unstructured":"Hiraoka A, et al. Atezolizumab plus Bevacizumab treatment for unresectable hepatocellular carcinoma: early clinical experience. Cancer Rep (Hoboken). 2022;5:e1464. https:\/\/doi.org\/10.1002\/cnr2.1464.","journal-title":"Cancer Rep (Hoboken)"},{"key":"1792_CR71","doi-asserted-by":"publisher","first-page":"e30871","DOI":"10.1097\/md.0000000000030871","volume":"101","author":"R Sugimoto","year":"2022","unstructured":"Sugimoto R, et al. Atezolizumab plus Bevacizumab treatment for unresectable hepatocellular carcinoma progressing after molecular targeted therapy: a multicenter prospective observational study. Medicine (Baltimore). 2022;101:e30871. https:\/\/doi.org\/10.1097\/md.0000000000030871.","journal-title":"Medicine (Baltimore)"},{"key":"1792_CR72","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1111\/hepr.13693","volume":"51","author":"T Sho","year":"2021","unstructured":"Sho T, et al. Early response and safety of Atezolizumab plus Bevacizumab for unresectable hepatocellular carcinoma in patients who do not meet IMbrave150 eligibility criteria. Hepatol Res. 2021;51:979\u201389. https:\/\/doi.org\/10.1111\/hepr.13693.","journal-title":"Hepatol Res"},{"key":"1792_CR73","doi-asserted-by":"publisher","first-page":"112933","DOI":"10.1016\/j.ejca.2023.05.021","volume":"189","author":"M Persano","year":"2023","unstructured":"Persano M, et al. Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments in hepatocellular carcinoma patients. Eur J Cancer. 2023;189:112933. https:\/\/doi.org\/10.1016\/j.ejca.2023.05.021.","journal-title":"Eur J Cancer"},{"key":"1792_CR74","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1159\/000515552","volume":"10","author":"K Koroki","year":"2021","unstructured":"Koroki K, et al. Posttreatment after lenvatinib in patients with advanced hepatocellular carcinoma. Liver Cancer. 2021;10:473\u201384. https:\/\/doi.org\/10.1159\/000515552.","journal-title":"Liver Cancer"},{"key":"1792_CR75","doi-asserted-by":"publisher","first-page":"3665","DOI":"10.1007\/s00432-021-03602-w","volume":"147","author":"A Casadei-Gardini","year":"2021","unstructured":"Casadei-Gardini A, et al. Regorafenib versus cabozantinib as second-line treatment after sorafenib for unresectable hepatocellular carcinoma: matching-adjusted indirect comparison analysis. J Cancer Res Clin Oncol. 2021;147:3665\u201371. https:\/\/doi.org\/10.1007\/s00432-021-03602-w.","journal-title":"J Cancer Res Clin Oncol"},{"key":"1792_CR76","doi-asserted-by":"publisher","first-page":"2678","DOI":"10.1007\/s12325-020-01378-y","volume":"37","author":"RK Kelley","year":"2020","unstructured":"Kelley RK, et al. Comparative efficacy of cabozantinib and regorafenib for advanced hepatocellular carcinoma. Adv Ther. 2020;37:2678\u201395. https:\/\/doi.org\/10.1007\/s12325-020-01378-y.","journal-title":"Adv Ther"},{"key":"1792_CR77","doi-asserted-by":"publisher","first-page":"300","DOI":"10.3747\/co.27.6583","volume":"27","author":"S Delos Santos","year":"2020","unstructured":"Delos Santos S, et al. A systematic review and network meta-analysis of second-line therapy in hepatocellular carcinoma. Curr Oncol. 2020;27:300\u20136. https:\/\/doi.org\/10.3747\/co.27.6583.","journal-title":"Curr Oncol"},{"key":"1792_CR78","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.4251\/wjgo.v14.i8.1510","volume":"14","author":"X Adhoute","year":"2022","unstructured":"Adhoute X, et al. Second-line therapy for advanced hepatocellular carcinoma with regorafenib or cabozantinib: multicenter French clinical experience in real-life after matching. World J Gastrointest Oncol. 2022;14:1510\u201327. https:\/\/doi.org\/10.4251\/wjgo.v14.i8.1510.","journal-title":"World J Gastrointest Oncol"},{"key":"1792_CR79","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1159\/000527403","volume":"12","author":"P Merle","year":"2023","unstructured":"Merle P, et al. Regorafenib versus Cabozantinib as a second-line treatment for advanced hepatocellular carcinoma: an anchored matching-adjusted indirect comparison of efficacy and safety. Liver Cancer. 2023;12:145\u201355. https:\/\/doi.org\/10.1159\/000527403.","journal-title":"Liver Cancer"},{"key":"1792_CR80","doi-asserted-by":"publisher","first-page":"2472","DOI":"10.1007\/s12325-021-01700-2","volume":"38","author":"J Trojan","year":"2021","unstructured":"Trojan J, et al. Comparative efficacy of Cabozantinib and Ramucirumab after Sorafenib for patients with hepatocellular carcinoma and Alpha-fetoprotein \u2265 400 ng\/mL: a matching-adjusted indirect comparison. Adv Ther. 2021;38:2472\u201390. https:\/\/doi.org\/10.1007\/s12325-021-01700-2.","journal-title":"Adv Ther"},{"key":"1792_CR81","doi-asserted-by":"publisher","first-page":"e204930","DOI":"10.1001\/jamaoncol.2020.4930","volume":"6","author":"MB Sonbol","year":"2020","unstructured":"Sonbol MB, et al. Systemic therapy and sequencing options in advanced hepatocellular carcinoma: a systematic review and network meta-analysis. JAMA Oncol. 2020;6:e204930. https:\/\/doi.org\/10.1001\/jamaoncol.2020.4930.","journal-title":"JAMA Oncol"},{"key":"1792_CR82","doi-asserted-by":"publisher","first-page":"e27013","DOI":"10.1097\/md.0000000000027013","volume":"100","author":"J Chen","year":"2021","unstructured":"Chen J, Wang J, Xie F. Comparative efficacy and safety for second-line treatment with ramucirumab, regorafenib, and cabozantinib in patients with advanced hepatocellular carcinoma progressed on sorafenib treatment: a network meta-analysis. Medicine (Baltimore). 2021;100:e27013. https:\/\/doi.org\/10.1097\/md.0000000000027013.","journal-title":"Medicine (Baltimore)"},{"key":"1792_CR83","doi-asserted-by":"publisher","first-page":"343","DOI":"10.2217\/cer-2020-0236","volume":"10","author":"ND Parikh","year":"2021","unstructured":"Parikh ND, et al. Network meta-analysis of nivolumab plus ipilimumab in the second-line setting for advanced hepatocellular carcinoma. J Comp Eff Res. 2021;10:343\u201352. https:\/\/doi.org\/10.2217\/cer-2020-0236.","journal-title":"J Comp Eff Res"},{"key":"1792_CR84","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1159\/000525145","volume":"11","author":"A Casadei-Gardini","year":"2022","unstructured":"Casadei-Gardini A, et al. Real life study of Lenvatinib Therapy for hepatocellular carcinoma: RELEVANT Study. Liver Cancer. 2022;11:527\u201339. https:\/\/doi.org\/10.1159\/000525145.","journal-title":"Liver Cancer"},{"key":"1792_CR85","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1097\/meg.0000000000002466","volume":"35","author":"Y Kim","year":"2023","unstructured":"Kim Y, et al. Sorafenib versus nivolumab after lenvatinib treatment failure in patients with advanced hepatocellular carcinoma. Eur J Gastroenterol Hepatol. 2023;35:191\u20137. https:\/\/doi.org\/10.1097\/meg.0000000000002466.","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"1792_CR86","doi-asserted-by":"publisher","DOI":"10.1159\/000543666","author":"J Cheon","year":"2025","unstructured":"Cheon J, et al. Multicenter Phase 2 trial of second-line regorafenib in patients with unresectable hepatocellular carcinoma after progression on atezolizumab plus bevacizumab. Liver Cancer. 2025. https:\/\/doi.org\/10.1159\/000543666.","journal-title":"Liver Cancer"},{"key":"1792_CR87","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1002\/lci2.74","volume":"4","author":"K Nouso","year":"2023","unstructured":"Nouso K, et al. Characteristics of cabozantinib treatment in advanced hepatocellular carcinoma. Liver Cancer Int. 2023;4:101\u20138. https:\/\/doi.org\/10.1002\/lci2.74.","journal-title":"Liver Cancer Int"},{"key":"1792_CR88","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1111\/hepr.13845","volume":"53","author":"T Tomonari","year":"2023","unstructured":"Tomonari T, et al. Multicenter retrospective study of initial treatment outcome and feasibility of initiating dose reduction of cabozantinib in unresectable hepatocellular carcinoma. Hepatol Res. 2023;53:172\u20138. https:\/\/doi.org\/10.1111\/hepr.13845.","journal-title":"Hepatol Res"},{"key":"1792_CR89","doi-asserted-by":"publisher","first-page":"2952","DOI":"10.3390\/cancers15112952","volume":"15","author":"T Kuzuya","year":"2023","unstructured":"Kuzuya T, et al. Clinical outcomes of Cabozantinib in patients previously treated with Atezolizumab\/Bevacizumab for advanced hepatocellular carcinoma-importance of good liver function and good performance status. Cancers (Basel). 2023;15:2952.","journal-title":"Cancers (Basel)"},{"key":"1792_CR90","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1038\/s41586-021-03362-0","volume":"592","author":"D Pfister","year":"2021","unstructured":"Pfister D, et al. NASH limits anti-tumour surveillance in immunotherapy-treated HCC. Nature. 2021;592:450\u20136. https:\/\/doi.org\/10.1038\/s41586-021-03362-0.","journal-title":"Nature"},{"key":"1792_CR91","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1007\/s12072-022-10392-x","volume":"16","author":"CT Chen","year":"2022","unstructured":"Chen CT, et al. Prognosis and treatment pattern of advanced hepatocellular carcinoma after failure of first-line atezolizumab and bevacizumab treatment. Hepatol Int. 2022;16:1199\u2013207. https:\/\/doi.org\/10.1007\/s12072-022-10392-x.","journal-title":"Hepatol Int"},{"key":"1792_CR92","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1159\/000514312","volume":"10","author":"M Kudo","year":"2021","unstructured":"Kudo M. Sequential therapy for hepatocellular carcinoma after failure of atezolizumab plus bevacizumab combination therapy. Liver Cancer. 2021;10:85\u201393.","journal-title":"Liver Cancer"},{"key":"1792_CR93","doi-asserted-by":"publisher","first-page":"3455","DOI":"10.1002\/cncr.26540","volume":"118","author":"SE Abdullah","year":"2012","unstructured":"Abdullah SE, Perez-Soler R. Mechanisms of resistance to vascular endothelial growth factor blockade. Cancer. 2012;118:3455\u201367. https:\/\/doi.org\/10.1002\/cncr.26540.","journal-title":"Cancer"},{"key":"1792_CR94","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s11060-010-0480-6","volume":"104","author":"S Grau","year":"2011","unstructured":"Grau S, et al. Bevacizumab can induce reactivity to VEGF-C and -D in human brain and tumour derived endothelial cells. J Neurooncol. 2011;104:103\u201312. https:\/\/doi.org\/10.1007\/s11060-010-0480-6.","journal-title":"J Neurooncol"},{"key":"1792_CR95","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/bjc.2015.209","volume":"113","author":"AJ Weickhardt","year":"2015","unstructured":"Weickhardt AJ, et al. Vascular endothelial growth factor D expression is a potential biomarker of Bevacizumab benefit in colorectal cancer. Br J Cancer. 2015;113:37\u201345. https:\/\/doi.org\/10.1038\/bjc.2015.209.","journal-title":"Br J Cancer"},{"key":"1792_CR96","doi-asserted-by":"publisher","first-page":"e77117","DOI":"10.1371\/journal.pone.0077117","volume":"8","author":"CH Lieu","year":"2013","unstructured":"Lieu CH, et al. The association of alternate VEGF ligands with resistance to Anti-VEGF therapy in metastatic colorectal cancer. PLoS One. 2013;8:e77117. https:\/\/doi.org\/10.1371\/journal.pone.0077117.","journal-title":"PLoS One"},{"key":"1792_CR97","doi-asserted-by":"publisher","unstructured":"Yang, Z et al. (2023) Changes in serum growth factors during resistance to Atezolizumab plus Bevacizumab treatment in patients with unresectable hepatocellular carcinoma. Cancers (Basel) 15. https:\/\/doi.org\/10.3390\/cancers15030593","DOI":"10.3390\/cancers15030593"},{"key":"1792_CR98","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.150735","author":"Y Zhang","year":"2021","unstructured":"Zhang Y, et al. VEGFR2 activity on myeloid cells mediates immune suppression in the tumor microenvironment. JCI Insight. 2021. https:\/\/doi.org\/10.1172\/jci.insight.150735.","journal-title":"JCI Insight"},{"key":"1792_CR99","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1158\/0008-5472.Can-12-2325","volume":"73","author":"M Terme","year":"2013","unstructured":"Terme M, et al. VEGFA-VEGFR pathway blockade inhibits tumor-induced regulatory T-cell proliferation in colorectal cancer. Cancer Res. 2013;73:539\u201349. https:\/\/doi.org\/10.1158\/0008-5472.Can-12-2325.","journal-title":"Cancer Res"},{"key":"1792_CR100","doi-asserted-by":"publisher","first-page":"4196","DOI":"10.1158\/0008-5472.Can-18-3657","volume":"79","author":"C Tacconi","year":"2019","unstructured":"Tacconi C, et al. Activation of the VEGFC\/VEGFR3 Pathway induces tumor immune escape in colorectal cancer. Cancer Res. 2019;79:4196\u2013210. https:\/\/doi.org\/10.1158\/0008-5472.Can-18-3657.","journal-title":"Cancer Res"},{"key":"1792_CR101","doi-asserted-by":"publisher","first-page":"100778","DOI":"10.1016\/j.gastha.2025.100778","volume":"5","author":"G Sugiyama","year":"2026","unstructured":"Sugiyama G, et al. Vascular endothelial growth factor receptor 2-targeted therapy suppresses the progression of Alpha-Fetoprotein-positive hepatocellular carcinoma after combination therapy with Anti-Programmed Death-Ligand 1 and Anti-Vascular Endothelial Growth Factor-A antibodies. Gastro Hep Adv. 2026;5:100778. https:\/\/doi.org\/10.1016\/j.gastha.2025.100778.","journal-title":"Gastro Hep Adv"},{"key":"1792_CR102","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/s41392-024-02075-w","volume":"10","author":"J Zheng","year":"2025","unstructured":"Zheng J, et al. Hepatocellular carcinoma: signaling pathways and therapeutic advances. Signal Transduct Target Ther. 2025;10:35. https:\/\/doi.org\/10.1038\/s41392-024-02075-w.","journal-title":"Signal Transduct Target Ther"},{"key":"1792_CR103","doi-asserted-by":"publisher","first-page":"1776","DOI":"10.1002\/hep4.1927","volume":"6","author":"R Sharma","year":"2022","unstructured":"Sharma R, et al. Patterns and outcomes of subsequent therapy after immune checkpoint inhibitor discontinuation in HCC. Hepatol Commun. 2022;6:1776\u201385.","journal-title":"Hepatol Commun"},{"key":"1792_CR104","doi-asserted-by":"publisher","first-page":"2559","DOI":"10.1007\/s00432-022-04115-w","volume":"149","author":"S Armstrong","year":"2023","unstructured":"Armstrong S, et al. TKIs beyond immunotherapy predict improved survival in advanced HCC. J Cancer Res Clin Oncol. 2023;149:2559\u201374. https:\/\/doi.org\/10.1007\/s00432-022-04115-w.","journal-title":"J Cancer Res Clin Oncol"},{"key":"1792_CR105","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1111\/liv.15502","volume":"43","author":"T Talbot","year":"2023","unstructured":"Talbot T, et al. Progression patterns and therapeutic sequencing following immune checkpoint inhibition for hepatocellular carcinoma: An international observational study. Liver Int. 2023;43:695\u2013707. https:\/\/doi.org\/10.1111\/liv.15502.","journal-title":"Liver Int"},{"key":"1792_CR106","doi-asserted-by":"publisher","first-page":"101232","DOI":"10.1016\/j.jhepr.2024.101232","volume":"7","author":"M Wu","year":"2025","unstructured":"Wu M, et al. Second-line treatment patterns and outcomes in advanced HCC after progression on atezolizumab\/bevacizumab. JHEP Rep. 2025;7:101232. https:\/\/doi.org\/10.1016\/j.jhepr.2024.101232.","journal-title":"JHEP Rep"},{"key":"1792_CR107","doi-asserted-by":"publisher","first-page":"4673","DOI":"10.21873\/anticanres.16663","volume":"43","author":"H Muto","year":"2023","unstructured":"Muto H, et al. Clinical outcomes with lenvatinib in patients previously treated with atezolizumab\/bevacizumab for advanced hepatocellular carcinoma. Anticancer Res. 2023;43:4673\u201382. https:\/\/doi.org\/10.21873\/anticanres.16663.","journal-title":"Anticancer Res"},{"key":"1792_CR108","doi-asserted-by":"publisher","first-page":"3048","DOI":"10.3390\/cancers12103048","volume":"12","author":"T Aoki","year":"2020","unstructured":"Aoki T, et al. Exploratory analysis of lenvatinib therapy in patients with unresectable hepatocellular carcinoma who have failed prior PD\u2212 1\/PD-L1 checkpoint blockade. Cancers (Basel). 2020;12:3048.","journal-title":"Cancers (Basel)"},{"key":"1792_CR109","doi-asserted-by":"publisher","first-page":"S613","DOI":"10.1016\/j.annonc.2023.09.2144","volume":"34","author":"D Ahn","year":"2023","unstructured":"Ahn D, et al. Real-world clinical outcomes of cabozantinib (cabo) as a second-line (2L) treatment for advanced hepatocellular carcinoma (aHCC). Ann Oncol. 2023;34:S613. https:\/\/doi.org\/10.1016\/j.annonc.2023.09.2144.","journal-title":"Ann Oncol"},{"key":"1792_CR110","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1159\/000512781","volume":"10","author":"C Yoo","year":"2021","unstructured":"Yoo C, et al. Clinical outcomes with multikinase inhibitors after progression on first-line atezolizumab plus bevacizumab in patients with advanced hepatocellular carcinoma: a multinational multicenter retrospective study. Liver Cancer. 2021;10:107\u201314.","journal-title":"Liver Cancer"},{"key":"1792_CR111","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1159\/000531316","volume":"101","author":"A Hiraoka","year":"2023","unstructured":"Hiraoka A, et al. Lenvatinib as second-line treatment after atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma: clinical results show importance of hepatic reserve function. Oncology. 2023;101:624\u201333. https:\/\/doi.org\/10.1159\/000531316.","journal-title":"Oncology"},{"key":"1792_CR112","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14215173","author":"MH Storandt","year":"2022","unstructured":"Storandt MH, et al. Cabozantinib following immunotherapy in patients with advanced hepatocellular carcinoma. Cancers (Basel). 2022. https:\/\/doi.org\/10.3390\/cancers14215173.","journal-title":"Cancers (Basel)"},{"key":"1792_CR113","doi-asserted-by":"publisher","first-page":"S1454","DOI":"10.1016\/j.annonc.2022.10.099","volume":"33","author":"S Chan","year":"2022","unstructured":"Chan S, et al. LBA1 a phase II clinical trial to study the efficacy of cabozantinib in patients with hepatocellular carcinoma refractory to immune checkpoint inhibitor-based treatment. Ann Oncol. 2022;33:S1454. https:\/\/doi.org\/10.1016\/j.annonc.2022.10.099.","journal-title":"Ann Oncol"},{"key":"1792_CR114","doi-asserted-by":"publisher","first-page":"e526","DOI":"10.1093\/oncolo\/oyad090","volume":"28","author":"T Fukushima","year":"2023","unstructured":"Fukushima T, et al. Association between immune-related adverse events and survival in patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab. Oncologist. 2023;28:e526\u201333. https:\/\/doi.org\/10.1093\/oncolo\/oyad090.","journal-title":"Oncologist"},{"key":"1792_CR115","doi-asserted-by":"publisher","DOI":"10.3350\/cmh.2023.0553","author":"YE Chon","year":"2024","unstructured":"Chon YE, et al. Sorafenib vs. lenvatinib in advanced hepatocellular carcinoma after atezolizumab\/bevacizumab failure: a real-world study. Clin Mol Hepatol. 2024. https:\/\/doi.org\/10.3350\/cmh.2023.0553.","journal-title":"Clin Mol Hepatol"},{"key":"1792_CR116","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1159\/000540969","volume":"14","author":"C-k Lee","year":"2024","unstructured":"Lee C-k, et al. Real-world study of systemic treatment after first-line Atezolizumab plus Bevacizumab for hepatocellular carcinoma in Asia-Pacific Countries. Liver Cancer. 2024;14:127\u201341. https:\/\/doi.org\/10.1159\/000540969.","journal-title":"Liver Cancer"},{"key":"1792_CR117","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1016\/j.jhep.2021.07.004","volume":"75","author":"J Bruix","year":"2021","unstructured":"Bruix J, Chan SL, Galle PR, Rimassa L, Sangro B. Systemic treatment of hepatocellular carcinoma: an EASL position paper. J Hepatol. 2021;75:960\u201374. https:\/\/doi.org\/10.1016\/j.jhep.2021.07.004.","journal-title":"J Hepatol"},{"key":"1792_CR118","doi-asserted-by":"publisher","first-page":"1922","DOI":"10.1097\/hep.0000000000000466","volume":"78","author":"AG Singal","year":"2023","unstructured":"Singal AG, et al. AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma. Hepatology. 2023;78:1922\u201365. https:\/\/doi.org\/10.1097\/hep.0000000000000466.","journal-title":"Hepatology"},{"key":"1792_CR119","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1053\/j.gastro.2021.12.276","volume":"162","author":"GL Su","year":"2022","unstructured":"Su GL, et al. AGA clinical practice guideline on systemic therapy for hepatocellular carcinoma. Gastroenterology. 2022;162:920\u201334. https:\/\/doi.org\/10.1053\/j.gastro.2021.12.276.","journal-title":"Gastroenterology"},{"key":"1792_CR120","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1200\/JCO.2019.37.4_suppl.361","volume":"37","author":"TC Yau","year":"2019","unstructured":"Yau TC, et al. Outcomes of tyrosine kinase inhibitors (TKI) after immunotherapy in unresectable or advanced hepatocellular carcinoma (HCC) patients. J Clin Oncol. 2019;37:361\u2013361. https:\/\/doi.org\/10.1200\/JCO.2019.37.4_suppl.361.","journal-title":"J Clin Oncol"},{"key":"1792_CR121","doi-asserted-by":"publisher","first-page":"e16181","DOI":"10.1200\/JCO.2021.39.15_suppl.e16181","volume":"39","author":"T Yau","year":"2021","unstructured":"Yau T, et al. Outcomes of tyrosine kinase inhibitors after immunotherapy in advanced hepatocellular carcinoma: A multi-center study. J Clin Oncol. 2021;39:e16181\u2013e16181. https:\/\/doi.org\/10.1200\/JCO.2021.39.15_suppl.e16181.","journal-title":"J Clin Oncol"},{"key":"1792_CR122","doi-asserted-by":"publisher","first-page":"e16195","DOI":"10.1200\/JCO.2023.41.16_suppl.e16195","volume":"41","author":"T Aldawoodi","year":"2023","unstructured":"Aldawoodi T, et al. Treatment patterns post atezolizumab plus bevacizumab for advanced hepatocellular carcinoma: Real-world analysis at Veterans Health Administration comparing lenvatinib vs. sorafenib. J Clin Oncol. 2023;41:e16195\u2013e16195. https:\/\/doi.org\/10.1200\/JCO.2023.41.16_suppl.e16195.","journal-title":"J Clin Oncol"},{"key":"1792_CR123","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1200\/JCO.2023.41.4_suppl.510","volume":"41","author":"Y Asaoka","year":"2023","unstructured":"Asaoka Y, et al. Real world data of systemic therapy for hepatocellular carcinoma in Japan: HERITAGE study. J Clin Oncol. 2023;41:510\u2013510. https:\/\/doi.org\/10.1200\/JCO.2023.41.4_suppl.510.","journal-title":"J Clin Oncol"},{"key":"1792_CR124","doi-asserted-by":"publisher","first-page":"175883592311894","DOI":"10.1177\/17588359231189425","volume":"15","author":"M Falette-Puisieux","year":"2023","unstructured":"Falette-Puisieux M, et al. Beyond Atezolizumab plus Bevacizumab in patients with advanced hepatocellular carcinoma: overall efficacy and safety of tyrosine kinase inhibitors in a real-world setting. Ther Adv Med Oncol. 2023;15:17588359231189424. https:\/\/doi.org\/10.1177\/17588359231189425.","journal-title":"Ther Adv Med Oncol"},{"key":"1792_CR125","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1200\/JCO.2024.42.3_suppl.477","volume":"42","author":"C Yoo","year":"2024","unstructured":"Yoo C, et al. Second-line regorafenib in patients (pts) with unresectable hepatocellular carcinoma (uHCC) after progression on first-line atezolizumab plus bevacizumab (Atezo-Bev): Phase 2 REGONEXT trial. J Clin Oncol. 2024;42:477\u2013477. https:\/\/doi.org\/10.1200\/JCO.2024.42.3_suppl.477.","journal-title":"J Clin Oncol"},{"key":"1792_CR126","doi-asserted-by":"publisher","first-page":"5406","DOI":"10.3390\/cancers15225406","volume":"15","author":"S Yano","year":"2023","unstructured":"Yano S, et al. Therapeutic efficacy and safety of Lenvatinib after Atezolizumab plus Bevacizumab for Unresectable Hepatocellular Carcinoma. Cancers (Basel). 2023;15:5406.","journal-title":"Cancers (Basel)"},{"key":"1792_CR127","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.21873\/anticanres.16286","volume":"43","author":"YH Chen","year":"2023","unstructured":"Chen YH, Chen YY, Wang JH, Hung CH. Efficacy and safety of Lenvatinib after progression on first-line Atezolizumab plus Bevacizumab treatment in advanced hepatocellular carcinoma patients. Anticancer Res. 2023;43:1377\u201384. https:\/\/doi.org\/10.21873\/anticanres.16286.","journal-title":"Anticancer Res"},{"key":"1792_CR128","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000510995","volume":"43","author":"J Trojan","year":"2020","unstructured":"Trojan J, Abou-Alfa GK, El-Khoueiry AB. Clinical activity of cabozantinib in patients with advanced hepatocellular carcinoma previously treated with anti-VEGF and immuno-oncology therapy: subgroup analysis from the phase 3 CELESTIAL trial. Oncol Res Treat. 2020;43:1\u2013292. https:\/\/doi.org\/10.1159\/000510995.","journal-title":"Oncol Res Treat"},{"key":"1792_CR129","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.jhep.2024.03.033","volume":"81","author":"SL Chan","year":"2024","unstructured":"Chan SL, et al. Multicentre phase II trial of cabozantinib in patients with hepatocellular carcinoma after immune checkpoint inhibitor treatment. J Hepatol. 2024;81:258\u201364. https:\/\/doi.org\/10.1016\/j.jhep.2024.03.033.","journal-title":"J Hepatol"},{"key":"1792_CR130","doi-asserted-by":"publisher","first-page":"4007","DOI":"10.1200\/JCO.2024.42.16_suppl.4007","volume":"42","author":"AB El-Khoueiry","year":"2024","unstructured":"El-Khoueiry AB, et al. International, open-label phase 2 study of regorafenib plus pembrolizumab in patients with advanced hepatocellular carcinoma (HCC) previously treated with immune checkpoint inhibitors (ICI). J Clin Oncol. 2024;42:4007\u20134007. https:\/\/doi.org\/10.1200\/JCO.2024.42.16_suppl.4007.","journal-title":"J Clin Oncol"},{"key":"1792_CR131","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1111\/hepr.13852","volume":"53","author":"S Shimose","year":"2023","unstructured":"Shimose S, et al. Significance of ramucirumab following atezolizumab plus bevacizumab therapy for hepatocellular carcinoma using real-world data. Hepatol Res. 2023;53:116\u201326. https:\/\/doi.org\/10.1111\/hepr.13852.","journal-title":"Hepatol Res"},{"key":"1792_CR132","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.21873\/anticanres.15667","volume":"42","author":"T Kuzuya","year":"2022","unstructured":"Kuzuya T, et al. Clinical outcomes of Ramucirumab as post-treatment following Atezolizumab\/Bevacizumab combination therapy in advanced hepatocellular carcinoma. Anticancer Res. 2022;42:1905\u201310. https:\/\/doi.org\/10.21873\/anticanres.15667.","journal-title":"Anticancer Res"},{"key":"1792_CR133","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1007\/s10637-024-01441-3","volume":"42","author":"K Kobayashi","year":"2024","unstructured":"Kobayashi K, et al. Ramucirumab for advanced hepatocellular carcinoma in the current real world: a Japanese single-arm study post-REACH-2 (The R-evolution study). Invest New Drugs. 2024;42:394\u2013404. https:\/\/doi.org\/10.1007\/s10637-024-01441-3.","journal-title":"Invest New Drugs"},{"key":"1792_CR134","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001945","author":"JSL Wong","year":"2021","unstructured":"Wong JSL, et al. Ipilimumab and nivolumab\/pembrolizumab in advanced hepatocellular carcinoma refractory to prior immune checkpoint inhibitors. J Immunother Cancer. 2021. https:\/\/doi.org\/10.1136\/jitc-2020-001945.","journal-title":"J Immunother Cancer"},{"key":"1792_CR135","doi-asserted-by":"publisher","first-page":"3065","DOI":"10.1007\/s00432-022-04206-8","volume":"149","author":"D Roessler","year":"2023","unstructured":"Roessler D, et al. Ipilimumab and nivolumab in advanced hepatocellular carcinoma after failure of prior immune checkpoint inhibitor-based combination therapies: a multicenter retrospective study. J Cancer Res Clin Oncol. 2023;149:3065\u201373. https:\/\/doi.org\/10.1007\/s00432-022-04206-8.","journal-title":"J Cancer Res Clin Oncol"},{"key":"1792_CR136","doi-asserted-by":"publisher","first-page":"e39289","DOI":"10.1097\/md.0000000000039289","volume":"103","author":"R Miura","year":"2024","unstructured":"Miura R, et al. Real-world efficacy and safety of durvalumab-tremelimumab as second-line systemic therapy after atezolizumab-bevacizumab in unresectable hepatocellular carcinoma. Medicine (Baltimore). 2024;103:e39289. https:\/\/doi.org\/10.1097\/md.0000000000039289.","journal-title":"Medicine (Baltimore)"},{"key":"1792_CR137","doi-asserted-by":"publisher","first-page":"100620","DOI":"10.1016\/j.jhepr.2022.100620","volume":"5","author":"B Scheiner","year":"2023","unstructured":"Scheiner B, et al. Efficacy and safety of immune checkpoint inhibitor rechallenge in individuals with hepatocellular carcinoma. JHEP Rep. 2023;5:100620. https:\/\/doi.org\/10.1016\/j.jhepr.2022.100620.","journal-title":"JHEP Rep"},{"key":"1792_CR138","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1159\/000541018","volume":"103","author":"M Persano","year":"2025","unstructured":"Persano M, et al. Lenvatinib versus Sorafenib Second-line therapy in patients with hepatocellular carcinoma progressed to Atezolizumab plus Bevacizumab: a Retrospective Real-World Study. Oncology. 2025;103:456\u201368. https:\/\/doi.org\/10.1159\/000541018.","journal-title":"Oncology"},{"key":"1792_CR139","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1007\/s00432-025-06085-1","volume":"151","author":"J Cheon","year":"2025","unstructured":"Cheon J, et al. Lenvatinib versus sorafenib as second-line therapy following progression on atezolizumab\u2013bevacizumab in patients with unresectable hepatocellular carcinoma: A multicenter retrospective study from Korea and Japan. J Cancer Res Clin Oncol. 2025;151:52. https:\/\/doi.org\/10.1007\/s00432-025-06085-1.","journal-title":"J Cancer Res Clin Oncol"},{"key":"1792_CR140","doi-asserted-by":"publisher","first-page":"101595","DOI":"10.1016\/j.jhepr.2025.101595","volume":"7","author":"P Lombardi","year":"2025","unstructured":"Lombardi P, et al. Lenvatinib vs. sorafenib as second-line treatment post atezolizumab plus bevacizumab for hepatocellular carcinoma: The LEVIATHAN study. JHEP Rep. 2025;7:101595. https:\/\/doi.org\/10.1016\/j.jhepr.2025.101595.","journal-title":"JHEP Rep"},{"key":"1792_CR141","doi-asserted-by":"publisher","first-page":"101917","DOI":"10.1016\/j.aohep.2025.101917","volume":"30","author":"K-C Lai","year":"2025","unstructured":"Lai K-C, et al. Real-world efficacy of cabozantinib alone or in combination with ICIs in heavily pretreated hepatocellular carcinoma: potential role of AXL and MET expression: Cabozantinib \u00b1 ICIs in pretreated HCC patients. Ann Hepatol. 2025;30:101917. https:\/\/doi.org\/10.1016\/j.aohep.2025.101917.","journal-title":"Ann Hepatol"},{"key":"1792_CR142","doi-asserted-by":"publisher","first-page":"1804","DOI":"10.1007\/s12072-024-10728-9","volume":"18","author":"KC Lai","year":"2024","unstructured":"Lai KC, et al. Efficacy and safety of durvalumab rechallenge in advanced hepatocellular carcinoma patients refractory to prior anti-PD-1 therapy. Hepatol Int. 2024;18:1804\u201314. https:\/\/doi.org\/10.1007\/s12072-024-10728-9.","journal-title":"Hepatol Int"},{"key":"1792_CR143","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1007\/s10637-024-01470-y","volume":"42","author":"N Mori","year":"2024","unstructured":"Mori N, et al. Treatment response to durvalumab plus tremelimumab after progression with previous immune checkpoint inhibitor in unresectable hepatocellular carcinoma. Invest New Drugs. 2024;42:559\u201365. https:\/\/doi.org\/10.1007\/s10637-024-01470-y.","journal-title":"Invest New Drugs"},{"key":"1792_CR144","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1007\/s11523-024-01092-7","volume":"19","author":"T Sho","year":"2024","unstructured":"Sho T, et al. Efficacy and safety of Durvalumab\/Tremelimumab in unresectable hepatocellular carcinoma as immune checkpoint inhibitor rechallenge following Atezolizumab\/Bevacizumab treatment. Target Oncol. 2024;19:769\u201378. https:\/\/doi.org\/10.1007\/s11523-024-01092-7.","journal-title":"Target Oncol"},{"key":"1792_CR145","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1111\/hepr.14160","volume":"55","author":"T Yonemoto","year":"2025","unstructured":"Yonemoto T, et al. Evaluating two rechallenge strategies of immune checkpoint inhibitors: Durvalumab plus tremelimumab in advanced hepatocellular carcinoma. Hepatol Res. 2025;55:718\u201329. https:\/\/doi.org\/10.1111\/hepr.14160.","journal-title":"Hepatol Res"},{"key":"1792_CR146","doi-asserted-by":"publisher","unstructured":"El-Khoueiry AB et al. (2026) A phase 1b study of botensilimab and balstilimab in treatment-refractory hepatocellular carcinoma. Liver Cancer. https:\/\/doi.org\/10.1159\/000551630","DOI":"10.1159\/000551630"},{"key":"1792_CR147","doi-asserted-by":"publisher","unstructured":"Chen J-K et al. (2026) Immune checkpoint inhibitor rechallenge in unresectable hepatocellular carcinoma: a multicenter efficacy and safety study. Liver Cancer. https:\/\/doi.org\/10.1159\/000551629","DOI":"10.1159\/000551629"},{"key":"1792_CR148","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1038\/s41591-022-01868-2","volume":"28","author":"AX Zhu","year":"2022","unstructured":"Zhu AX, et al. Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma. Nat Med. 2022;28:1599\u2013611. https:\/\/doi.org\/10.1038\/s41591-022-01868-2.","journal-title":"Nat Med"},{"key":"1792_CR149","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1016\/j.jhep.2024.12.016","volume":"82","author":"S Cappuyns","year":"2025","unstructured":"Cappuyns S, et al. Single-cell RNA sequencing-derived signatures define response patterns to atezolizumab + bevacizumab in advanced hepatocellular carcinoma. J Hepatol. 2025;82:1036\u201349. https:\/\/doi.org\/10.1016\/j.jhep.2024.12.016.","journal-title":"J Hepatol"},{"key":"1792_CR150","doi-asserted-by":"publisher","first-page":"C1150","DOI":"10.1152\/ajpcell.00511.2024","volume":"327","author":"J Ao","year":"2024","unstructured":"Ao J, et al. Dual effects of targeting neuropilin-1 in lenvatinib-resistant hepatocellular carcinoma: inhibition of tumor growth and angiogenesis. Am J Physiol Cell Physiol. 2024;327:C1150-c1161. https:\/\/doi.org\/10.1152\/ajpcell.00511.2024.","journal-title":"Am J Physiol Cell Physiol"},{"key":"1792_CR151","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1038\/s41401-022-01021-2","volume":"44","author":"P Fern\u00e1ndez-Palanca","year":"2023","unstructured":"Fern\u00e1ndez-Palanca P, et al. Hepatocellular carcinoma cells loss lenvatinib efficacy in vitro through autophagy and hypoxia response-derived neuropilin-1 degradation. Acta Pharmacol Sin. 2023;44:1066\u201382. https:\/\/doi.org\/10.1038\/s41401-022-01021-2.","journal-title":"Acta Pharmacol Sin"},{"key":"1792_CR152","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1007\/s12072-021-10212-8","volume":"15","author":"DWM Tai","year":"2021","unstructured":"Tai DWM, Le TBU, Prawira A, Ho RZW, Huynh H. Targeted inhibition of FGF19\/FGFR cascade improves antitumor immunity and response rate in hepatocellular carcinoma. Hepatol Int. 2021;15:1236\u201346. https:\/\/doi.org\/10.1007\/s12072-021-10212-8.","journal-title":"Hepatol Int"},{"key":"1792_CR153","doi-asserted-by":"publisher","first-page":"e007763","DOI":"10.1136\/jitc-2023-007763","volume":"11","author":"N Roussot","year":"2023","unstructured":"Roussot N, Lecuelle J, Dalens L, Truntzer C, Ghiringhelli F. FGF\/FGFR genomic amplification as a predictive biomarker for immune checkpoint blockade resistance: a short report. J Immunother Cancer. 2023;11:e007763. https:\/\/doi.org\/10.1136\/jitc-2023-007763.","journal-title":"J Immunother Cancer"},{"key":"1792_CR154","doi-asserted-by":"publisher","first-page":"218361","DOI":"10.1016\/j.canlet.2026.218361","volume":"646","author":"Y Jiang","year":"2026","unstructured":"Jiang Y, et al. Targeting FGFR1-regulated SPP1 signaling repolarizes immunosuppressive macrophages and sensitizes Hepatocellular Carcinoma to anti-PD-1 therapy. Cancer Lett. 2026;646:218361. https:\/\/doi.org\/10.1016\/j.canlet.2026.218361.","journal-title":"Cancer Lett"},{"key":"1792_CR155","doi-asserted-by":"publisher","first-page":"115955","DOI":"10.1016\/j.biopha.2023.115955","volume":"170","author":"C Guo","year":"2024","unstructured":"Guo C, et al. FGF19\/FGFR4 signaling contributes to hepatocellular carcinoma survival and immune escape by regulating IGF2BP1-mediated expression of PD-L1. Biomed Pharmacother. 2024;170:115955. https:\/\/doi.org\/10.1016\/j.biopha.2023.115955.","journal-title":"Biomed Pharmacother"},{"key":"1792_CR156","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1093\/gastro\/goaa042","volume":"9","author":"A Hiraoka","year":"2020","unstructured":"Hiraoka A, et al. Therapeutic efficacy of ramucirumab after lenvatinib for post-progression treatment of unresectable hepatocellular carcinoma. Gastroenterol Rep (Oxf). 2020;9:133\u20138. https:\/\/doi.org\/10.1093\/gastro\/goaa042.","journal-title":"Gastroenterol Rep (Oxf)"},{"key":"1792_CR157","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.jhep.2025.08.020","volume":"84","author":"H-D Kim","year":"2026","unstructured":"Kim H-D, et al. Multicenter single-arm phase II trial of lenvatinib in patients with advanced hepatocellular carcinoma after progression on first-line atezolizumab plus bevacizumab. J Hepatol. 2026;84:308\u201315. https:\/\/doi.org\/10.1016\/j.jhep.2025.08.020.","journal-title":"J Hepatol"},{"key":"1792_CR158","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1159\/000520278","volume":"11","author":"G Cabibbo","year":"2022","unstructured":"Cabibbo G, et al. First-line immune checkpoint inhibitor-based sequential therapies for advanced hepatocellular carcinoma: rationale for future trials. Liver Cancer. 2022;11:75\u201384. https:\/\/doi.org\/10.1159\/000520278.","journal-title":"Liver Cancer"},{"key":"1792_CR159","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1053\/j.gastro.2019.01.252","volume":"156","author":"H Li","year":"2019","unstructured":"Li H, et al. MET inhibitors promote liver tumor evasion of the immune response by stabilizing PDL1. Gastroenterology. 2019;156:1849-1861.e1813. https:\/\/doi.org\/10.1053\/j.gastro.2019.01.252.","journal-title":"Gastroenterology"},{"key":"1792_CR160","doi-asserted-by":"publisher","unstructured":"Ahn DH et al. (2025) Real-world clinical outcomes of cabozantinib as a second-line treatment for advanced hepatocellular carcinoma: a retrospective US claims analysis. Oncologist 30. https:\/\/doi.org\/10.1093\/oncolo\/oyaf252","DOI":"10.1093\/oncolo\/oyaf252"},{"key":"1792_CR161","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1158\/1078-0432.Ccr-18-1254","volume":"25","author":"MA Morse","year":"2019","unstructured":"Morse MA, et al. The role of angiogenesis in hepatocellular carcinoma. Clin Cancer Res. 2019;25:912\u201320. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-18-1254.","journal-title":"Clin Cancer Res"},{"key":"1792_CR162","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1158\/1535-7163.Mct-16-0866","volume":"16","author":"J-Y Ao","year":"2017","unstructured":"Ao J-Y, et al. Colony-stimulating factor 1 receptor blockade inhibits tumor growth by altering the polarization of tumor-associated macrophages in hepatocellular carcinoma. Mol Cancer Ther. 2017;16:1544\u201354. https:\/\/doi.org\/10.1158\/1535-7163.Mct-16-0866.","journal-title":"Mol Cancer Ther"},{"key":"1792_CR163","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1038\/s41591-024-02824-y","volume":"30","author":"H-D Kim","year":"2024","unstructured":"Kim H-D, et al. Regorafenib plus nivolumab in unresectable hepatocellular carcinoma: the phase 2 RENOBATE trial. Nat Med. 2024;30:699\u2013707. https:\/\/doi.org\/10.1038\/s41591-024-02824-y.","journal-title":"Nat Med"},{"key":"1792_CR164","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1093\/annonc\/mdy028","volume":"29","author":"P Carmeliet","year":"2018","unstructured":"Carmeliet P, Li X, Treps L, Conradi LC, Loges S. RAISEing VEGF-D\u2019s importance as predictive biomarker for ramucirumab in metastatic colorectal cancer patients. Ann Oncol. 2018;29:529\u201332. https:\/\/doi.org\/10.1093\/annonc\/mdy028.","journal-title":"Ann Oncol"},{"key":"1792_CR165","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1200\/JCO.2022.40.4_suppl.470","volume":"40","author":"HC Toh","year":"2022","unstructured":"Toh HC, et al. IMbrave150: Exploratory efficacy and safety in patients with unresectable hepatocellular carcinoma (HCC) treated with atezolizumab beyond radiological progression until loss of clinical benefit in a global phase III study. J Clin Oncol. 2022;40:470\u2013470. https:\/\/doi.org\/10.1200\/JCO.2022.40.4_suppl.470.","journal-title":"J Clin Oncol"},{"key":"1792_CR166","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/S0140-6736(23)00922-4","volume":"402","author":"SK Pal","year":"2023","unstructured":"Pal SK, et al. Atezolizumab plus cabozantinib versus cabozantinib monotherapy for patients with renal cell carcinoma after progression with previous immune checkpoint inhibitor treatment (CONTACT-03): a multicentre, randomised, open-label, phase 3 trial. Lancet. 2023;402:185\u201395. https:\/\/doi.org\/10.1016\/S0140-6736(23)00922-4.","journal-title":"Lancet"},{"key":"1792_CR167","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1016\/S0140-6736(24)01758-6","volume":"404","author":"TK Choueiri","year":"2024","unstructured":"Choueiri TK, et al. Tivozanib plus nivolumab versus tivozanib monotherapy in patients with renal cell carcinoma following an immune checkpoint inhibitor: results of the phase 3 TiNivo-2 Study. Lancet. 2024;404:1309\u201320. https:\/\/doi.org\/10.1016\/S0140-6736(24)01758-6.","journal-title":"Lancet"},{"key":"1792_CR168","doi-asserted-by":"publisher","first-page":"104289","DOI":"10.1016\/j.esmoop.2025.104289","volume":"10","author":"L Gramantieri","year":"2025","unstructured":"Gramantieri L, et al. Early CTLA4 increase in CD45+ blood cells: an emerging biomarker of atezolizumab-bevacizumab resistance and worse survival in advanced hepatocarcinoma. ESMO Open. 2025;10:104289. https:\/\/doi.org\/10.1016\/j.esmoop.2025.104289.","journal-title":"ESMO Open"},{"key":"1792_CR169","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1111\/cts.13127","volume":"15","author":"B Wu","year":"2022","unstructured":"Wu B, et al. Evaluation of atezolizumab immunogenicity: Clinical pharmacology (part 1). Clin Transl Sci. 2022;15:130\u201340. https:\/\/doi.org\/10.1111\/cts.13127.","journal-title":"Clin Transl Sci"},{"key":"1792_CR170","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1001\/jamaoncol.2022.4733","volume":"8","author":"C Kim","year":"2022","unstructured":"Kim C, et al. Association of high levels of antidrug antibodies against Atezolizumab with clinical outcomes and T-cell responses in patients with hepatocellular carcinoma. JAMA Oncol. 2022;8:1825\u20139. https:\/\/doi.org\/10.1001\/jamaoncol.2022.4733.","journal-title":"JAMA Oncol"},{"key":"1792_CR171","doi-asserted-by":"publisher","first-page":"e2500151","DOI":"10.1200\/oa-25-00151","volume":"3","author":"A Patwari","year":"2026","unstructured":"Patwari A, et al. PD-L2 landscape and correlation with outcome: an immunomic analysis. JCO Oncol Adv. 2026;3:e2500151. https:\/\/doi.org\/10.1200\/oa-25-00151.","journal-title":"JCO Oncol Adv"},{"key":"1792_CR172","doi-asserted-by":"publisher","first-page":"10377","DOI":"10.1038\/s41598-020-67497-2","volume":"10","author":"H Yasuoka","year":"2020","unstructured":"Yasuoka H, et al. Increased both PD\u2013L1 and PD\u2013L2 expressions on monocytes of patients with hepatocellular carcinoma was associated with a poor prognosis. Sci Rep. 2020;10:10377. https:\/\/doi.org\/10.1038\/s41598-020-67497-2.","journal-title":"Sci Rep"},{"key":"1792_CR173","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1158\/2767-9764.Crc-23-0072","volume":"3","author":"SL Alden","year":"2023","unstructured":"Alden SL, et al. Salvage Ipilimumab plus Nivolumab after Anti-PD-1\/PD-L1 Therapy in Advanced Hepatocellular Carcinoma. Cancer Res Commun. 2023;3:1312\u20137. https:\/\/doi.org\/10.1158\/2767-9764.Crc-23-0072.","journal-title":"Cancer Res Commun"},{"key":"1792_CR174","doi-asserted-by":"publisher","first-page":"e45385","DOI":"10.7759\/cureus.45385","volume":"15","author":"Y Kawamura","year":"2023","unstructured":"Kawamura Y, Akuta N, Fujiyama S, Suzuki F, Kumada H. Two cases of advanced hepatocellular carcinoma who responded well to the combination of Durvalumab plus Tremelimumab after disease progression during Atezolizumab plus Bevacizumab therapy under Bevacizumab withdrawal. Cureus. 2023;15:e45385. https:\/\/doi.org\/10.7759\/cureus.45385.","journal-title":"Cureus"},{"key":"1792_CR175","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.radonc.2020.11.033","volume":"156","author":"P Munoz-Schuffenegger","year":"2021","unstructured":"Munoz-Schuffenegger P, et al. Stereotactic body radiation therapy for hepatocellular carcinoma with Macrovascular invasion. Radiother Oncol. 2021;156:120\u20136. https:\/\/doi.org\/10.1016\/j.radonc.2020.11.033.","journal-title":"Radiother Oncol"},{"key":"1792_CR176","doi-asserted-by":"publisher","first-page":"e282","DOI":"10.1016\/j.jhep.2024.01.007","volume":"80","author":"LL Chan","year":"2024","unstructured":"Chan LL, Mok K, Chan SL. Radiotherapy following intrahepatic progression on immunotherapy in advanced hepatocellular carcinoma. J Hepatol. 2024;80:e282\u20133. https:\/\/doi.org\/10.1016\/j.jhep.2024.01.007.","journal-title":"J Hepatol"},{"key":"1792_CR177","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1001\/jamaoncol.2024.5403","volume":"11","author":"LA Dawson","year":"2025","unstructured":"Dawson LA, et al. Stereotactic body radiotherapy vs Sorafenib alone in Hepatocellular Carcinoma: The NRG Oncology\/RTOG 1112 Phase 3 Randomized Clinical Trial. JAMA Oncol. 2025;11:136\u201344. https:\/\/doi.org\/10.1001\/jamaoncol.2024.5403.","journal-title":"JAMA Oncol"},{"key":"1792_CR178","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1159\/000533425","volume":"13","author":"CL Chiang","year":"2024","unstructured":"Chiang CL, et al. Survival outcome analysis of stereotactic body radiotherapy and immunotherapy (SBRT-IO) versus SBRT-Alone in Unresectable Hepatocellular Carcinoma. Liver Cancer. 2024;13:265\u201376. https:\/\/doi.org\/10.1159\/000533425.","journal-title":"Liver Cancer"},{"key":"1792_CR179","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10102481","author":"KK Sindhu","year":"2022","unstructured":"Sindhu KK, et al. Oligoprogression of solid tumors on immune checkpoint inhibitors: the impact of local ablative radiation therapy. Biomedicines. 2022. https:\/\/doi.org\/10.3390\/biomedicines10102481.","journal-title":"Biomedicines"},{"key":"1792_CR180","doi-asserted-by":"publisher","first-page":"4640","DOI":"10.1002\/cam4.3116","volume":"9","author":"AS Fung","year":"2020","unstructured":"Fung AS, et al. Second-line treatment of hepatocellular carcinoma after sorafenib: characterizing treatments used over the past 10 years and real-world eligibility for cabozantinib, regorafenib, and ramucirumab. Cancer Med. 2020;9:4640\u20137. https:\/\/doi.org\/10.1002\/cam4.3116.","journal-title":"Cancer Med"},{"key":"1792_CR181","doi-asserted-by":"publisher","unstructured":"Lee SW, Lee TY, Yang SS, Huang YJ, Peng YC (2024) The impact of sequential therapies after first-line systemic therapies in unresectable hepatocellular carcinoma. J Clin Med 13. https:\/\/doi.org\/10.3390\/jcm13092612","DOI":"10.3390\/jcm13092612"},{"key":"1792_CR182","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1159\/000519868","volume":"11","author":"K Kobayashi","year":"2021","unstructured":"Kobayashi K, et al. Evolution of Survival impact of molecular target agents in patients with advanced hepatocellular carcinoma. Liver Cancer. 2021;11:48\u201360. https:\/\/doi.org\/10.1159\/000519868.","journal-title":"Liver Cancer"},{"key":"1792_CR183","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1001\/jamaoncol.2016.4115","volume":"3","author":"AX Zhu","year":"2017","unstructured":"Zhu AX, et al. Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma: analysis of REACH trial results by Child-Pugh score. JAMA Oncol. 2017;3:235\u201343. https:\/\/doi.org\/10.1001\/jamaoncol.2016.4115.","journal-title":"JAMA Oncol"},{"key":"1792_CR184","doi-asserted-by":"publisher","first-page":"2544","DOI":"10.1111\/liv.14573","volume":"40","author":"HD Kim","year":"2020","unstructured":"Kim HD, et al. Regorafenib in patients with advanced Child-Pugh B hepatocellular carcinoma: a multicentre retrospective study. Liver Int. 2020;40:2544\u201352. https:\/\/doi.org\/10.1111\/liv.14573.","journal-title":"Liver Int"},{"key":"1792_CR185","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1016\/j.jhep.2021.04.047","volume":"75","author":"M Kudo","year":"2021","unstructured":"Kudo M, et al. CheckMate 040 cohort 5: a phase I\/II study of nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh B cirrhosis. J Hepatol. 2021;75:600\u20139. https:\/\/doi.org\/10.1016\/j.jhep.2021.04.047.","journal-title":"J Hepatol"},{"key":"1792_CR186","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1001\/jamaoncol.2023.3284","volume":"9","author":"E Xie","year":"2023","unstructured":"Xie E, et al. Immune checkpoint inhibitors for Child-Pugh Class B advanced hepatocellular carcinoma: a systematic review and meta-analysis. JAMA Oncol. 2023;9:1423\u201331. https:\/\/doi.org\/10.1001\/jamaoncol.2023.3284.","journal-title":"JAMA Oncol"},{"key":"1792_CR187","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1038\/s41416-021-01532-5","volume":"126","author":"RK Kelley","year":"2022","unstructured":"Kelley RK, et al. Efficacy and safety of cabozantinib for patients with advanced hepatocellular carcinoma based on albumin-bilirubin grade. Br J Cancer. 2022;126:569\u201375. https:\/\/doi.org\/10.1038\/s41416-021-01532-5.","journal-title":"Br J Cancer"},{"key":"1792_CR188","doi-asserted-by":"publisher","first-page":"100215","DOI":"10.1016\/j.jhepr.2020.100215","volume":"3","author":"M Kudo","year":"2021","unstructured":"Kudo M, et al. Effect of ramucirumab on ALBI grade in patients with advanced HCC: results from REACH and REACH-2. JHEP Rep. 2021;3:100215. https:\/\/doi.org\/10.1016\/j.jhepr.2020.100215.","journal-title":"JHEP Rep"},{"key":"1792_CR189","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1186\/s12885-022-09453-z","volume":"22","author":"AB El-Khoueiry","year":"2022","unstructured":"El-Khoueiry AB, et al. Safety and efficacy of cabozantinib for patients with advanced hepatocellular carcinoma who advanced to Child-Pugh B liver function at study week 8: a retrospective analysis of the CELESTIAL randomised controlled trial. BMC Cancer. 2022;22:377. https:\/\/doi.org\/10.1186\/s12885-022-09453-z.","journal-title":"BMC Cancer"},{"key":"1792_CR190","doi-asserted-by":"publisher","first-page":"e26820","DOI":"10.1097\/md.0000000000026820","volume":"100","author":"H Muto","year":"2021","unstructured":"Muto H, et al. Transient deterioration of albumin\u2013bilirubin scores in early post-dose period of molecular targeted therapies in advanced hepatocellular carcinoma with 50% or higher liver occupation: A STROBE-compliant retrospective observational study. Medicine (Baltimore). 2021;100:e26820. https:\/\/doi.org\/10.1097\/md.0000000000026820.","journal-title":"Medicine (Baltimore)"},{"key":"1792_CR191","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14122975","author":"Y Yasui","year":"2022","unstructured":"Yasui Y, et al. Real-world data on ramucirumab therapy including patients who experienced two or more systemic treatments: a multicenter study. Cancers (Basel). 2022. https:\/\/doi.org\/10.3390\/cancers14122975.","journal-title":"Cancers (Basel)"},{"key":"1792_CR192","doi-asserted-by":"publisher","first-page":"1528138","DOI":"10.3389\/fonc.2024.1528138","volume":"14","author":"T Du","year":"2024","unstructured":"Du T, et al. CA19\u20139-related macrophage polarization drives poor prognosis in HCC after immune checkpoint inhibitor treatment. Front Oncol. 2024;14:1528138. https:\/\/doi.org\/10.3389\/fonc.2024.1528138.","journal-title":"Front Oncol"},{"key":"1792_CR193","doi-asserted-by":"publisher","first-page":"e74","DOI":"10.1038\/ctg.2014.22","volume":"6","author":"CC Hsu","year":"2015","unstructured":"Hsu CC, et al. Elevated CA19-9 is associated with increased mortality in a prospective cohort of hepatocellular carcinoma patients. Clin Transl Gastroenterol. 2015;6:e74. https:\/\/doi.org\/10.1038\/ctg.2014.22.","journal-title":"Clin Transl Gastroenterol"},{"key":"1792_CR194","doi-asserted-by":"publisher","first-page":"4848","DOI":"10.1158\/1078-0432.Ccr-20-4219","volume":"27","author":"RS Finn","year":"2021","unstructured":"Finn RS, et al. Pharmacodynamic biomarkers predictive of survival benefit with Lenvatinib in Unresectable Hepatocellular Carcinoma: from the Phase III REFLECT Study. Clin Cancer Res. 2021;27:4848\u201358. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-20-4219.","journal-title":"Clin Cancer Res"},{"key":"1792_CR195","doi-asserted-by":"publisher","first-page":"5303","DOI":"10.1038\/s41598-021-84117-9","volume":"11","author":"H Kanzaki","year":"2021","unstructured":"Kanzaki H, et al. The impact of FGF19\/FGFR4 signaling inhibition in antitumor activity of multi-kinase inhibitors in hepatocellular carcinoma. Sci Rep. 2021;11:5303. https:\/\/doi.org\/10.1038\/s41598-021-84117-9.","journal-title":"Sci Rep"},{"key":"1792_CR196","doi-asserted-by":"publisher","first-page":"293","DOI":"10.3390\/cancers12020293","volume":"12","author":"M Chuma","year":"2020","unstructured":"Chuma M, et al. Early changes in circulating FGF19 and Ang-2 levels as possible predictive biomarkers of clinical response to Lenvatinib therapy in hepatocellular carcinoma. Cancers (Basel). 2020;12:293.","journal-title":"Cancers (Basel)"},{"key":"1792_CR197","doi-asserted-by":"publisher","first-page":"e00179","DOI":"10.14309\/ctg.0000000000000179","volume":"11","author":"M Yamauchi","year":"2020","unstructured":"Yamauchi M, et al. Tumor fibroblast growth factor receptor 4 level predicts the efficacy of Lenvatinib in patients with advanced hepatocellular carcinoma. Clin Transl Gastroenterol. 2020;11:e00179. https:\/\/doi.org\/10.14309\/ctg.0000000000000179.","journal-title":"Clin Transl Gastroenterol"},{"key":"1792_CR198","doi-asserted-by":"publisher","first-page":"2544","DOI":"10.1002\/hep.31921","volume":"74","author":"C Yi","year":"2021","unstructured":"Yi C, et al. Lenvatinib targets FGF receptor 4 to enhance antitumor immune response of anti\u2013Programmed Cell Death\u20101 in HCC. Hepatology. 2021;74:2544\u201360. https:\/\/doi.org\/10.1002\/hep.31921.","journal-title":"Hepatology"},{"key":"1792_CR199","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1016\/j.jhep.2019.06.001","volume":"71","author":"J Calderaro","year":"2019","unstructured":"Calderaro J, Ziol M, Paradis V, Zucman-Rossi J. Molecular and histological correlations in liver cancer. J Hepatol. 2019;71:616\u201330. https:\/\/doi.org\/10.1016\/j.jhep.2019.06.001.","journal-title":"J Hepatol"},{"key":"1792_CR200","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1053\/j.gastro.2019.01.261","volume":"156","author":"M Teufel","year":"2019","unstructured":"Teufel M, et al. Biomarkers associated with response to regorafenib in patients with hepatocellular carcinoma. Gastroenterology. 2019;156:1731\u201341.","journal-title":"Gastroenterology"},{"key":"1792_CR201","doi-asserted-by":"publisher","first-page":"2116","DOI":"10.1158\/1078-0432.Ccr-18-2293","volume":"25","author":"JJ Harding","year":"2019","unstructured":"Harding JJ, et al. Prospective genotyping of Hepatocellular Carcinoma: clinical implications of next-generation sequencing for matching patients to targeted and immune therapies. Clin Cancer Res. 2019;25:2116\u201326. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-18-2293.","journal-title":"Clin Cancer Res"},{"key":"1792_CR202","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1038\/s41588-025-02496-5","volume":"58","author":"A Krishna","year":"2026","unstructured":"Krishna A, et al. Mutational scanning reveals oncogenic CTNNB1 mutations have diverse effects on signaling. Nat Genet. 2026;58:366\u201375. https:\/\/doi.org\/10.1038\/s41588-025-02496-5.","journal-title":"Nat Genet"},{"key":"1792_CR203","doi-asserted-by":"publisher","unstructured":"Laimon Y et al. (2025) 831 AXL receptor tyrosine kinase expression in metastatic renal cell carcinoma: Insights from the METEOR trial. Lab Invest 105. https:\/\/doi.org\/10.1016\/j.labinv.2024.103064","DOI":"10.1016\/j.labinv.2024.103064"},{"key":"1792_CR204","doi-asserted-by":"publisher","first-page":"6080","DOI":"10.1158\/1078-0432.Ccr-19-1135","volume":"25","author":"A Flaifel","year":"2019","unstructured":"Flaifel A, et al. PD-L1 expression and clinical outcomes to Cabozantinib, Everolimus, and Sunitinib in patients with Metastatic Renal Cell Carcinoma: analysis of the randomized clinical trials METEOR and CABOSUN. Clin Cancer Res. 2019;25:6080\u20138. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-19-1135.","journal-title":"Clin Cancer Res"},{"key":"1792_CR205","doi-asserted-by":"publisher","first-page":"747","DOI":"10.14218\/jcth.2022.00212","volume":"11","author":"YB Sang","year":"2023","unstructured":"Sang YB, Kim G, Hwang S, Kang H, Chon HJ. Dramatic response to Cabozantinib in a patient with refractory hepatocellular carcinoma with c-MET amplification. J Clin Transl Hepatol. 2023;11:747\u201350. https:\/\/doi.org\/10.14218\/jcth.2022.00212.","journal-title":"J Clin Transl Hepatol"},{"key":"1792_CR206","doi-asserted-by":"publisher","unstructured":"Qin S et al. (2024) Activity of Tepotinib in Hepatocellular Carcinoma with high-level MET amplification: preclinical and clinical evidence. JCO Oncol Pract e2300328. https:\/\/doi.org\/10.1200\/po.23.00328","DOI":"10.1200\/po.23.00328"},{"key":"1792_CR207","doi-asserted-by":"publisher","first-page":"1196211","DOI":"10.3389\/fonc.2023.1196211","volume":"13","author":"Y Gu","year":"2023","unstructured":"Gu Y, Xiao M, Chen Z, Li Q. Advanced hepatocellular carcinoma with MET-amplified contained excellent response to crizotinib: a case report. Front Oncol. 2023;13:1196211. https:\/\/doi.org\/10.3389\/fonc.2023.1196211.","journal-title":"Front Oncol"},{"key":"1792_CR208","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1016\/j.jhep.2017.06.026","volume":"67","author":"J Bruix","year":"2017","unstructured":"Bruix J, et al. Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: analysis of two phase III studies. J Hepatol. 2017;67:999\u20131008. https:\/\/doi.org\/10.1016\/j.jhep.2017.06.026.","journal-title":"J Hepatol"},{"key":"1792_CR209","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1007\/s00109-026-02645-1","volume":"104","author":"A Courtois","year":"2026","unstructured":"Courtois A, et al. Alcohol induces sorafenib resistance in hepatocellular carcinoma: A translational study. J Mol Med (Berl). 2026;104:34. https:\/\/doi.org\/10.1007\/s00109-026-02645-1.","journal-title":"J Mol Med (Berl)"},{"key":"1792_CR210","doi-asserted-by":"publisher","first-page":"S63","DOI":"10.1016\/j.annonc.2025.05.162","volume":"36","author":"Q Cheng","year":"2025","unstructured":"Cheng Q, et al. 149MO Irpagratinib (ABSK-011) plus atezolizumab in first-line (1L) and immune checkpoint inhibitors (ICIs) treated advanced hepatocellular carcinoma (HCC) with FGF19 overexpression (+): Updated results of the phase II ABSK-011\u2013201 study. Ann Oncol. 2025;36:S63. https:\/\/doi.org\/10.1016\/j.annonc.2025.05.162.","journal-title":"Ann Oncol"},{"key":"1792_CR211","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1200\/JCO.2025.43.4_suppl.583","volume":"43","author":"MA Ahmed","year":"2025","unstructured":"Ahmed MA, et al. TYRA-430: First reversible FGFR4\/3 inhibitor designed to overcome current challenges in FGF19-driven hepatocellular carcinoma treatment. J Clin Oncol. 2025;43:583\u2013583. https:\/\/doi.org\/10.1200\/JCO.2025.43.4_suppl.583.","journal-title":"J Clin Oncol"},{"key":"1792_CR212","doi-asserted-by":"publisher","unstructured":"Fu Q et al. (2023) RUNX-3-expressing CAR T cells targeting glypican-3 in patients with heavily pretreated advanced hepatocellular carcinoma: a phase I trial. eClinicalMedicine 63. https:\/\/doi.org\/10.1016\/j.eclinm.2023.102175","DOI":"10.1016\/j.eclinm.2023.102175"},{"key":"1792_CR213","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1038\/s43018-023-00609-9","volume":"4","author":"A Rialdi","year":"2023","unstructured":"Rialdi A, et al. WNTinib is a multi-kinase inhibitor with specificity against \u03b2-catenin mutant hepatocellular carcinoma. Nat Cancer. 2023;4:1157\u201375. https:\/\/doi.org\/10.1038\/s43018-023-00609-9.","journal-title":"Nat Cancer"},{"key":"1792_CR214","doi-asserted-by":"publisher","first-page":"S1914","DOI":"10.1016\/j.annonc.2025.10.237","volume":"36","author":"G Choi","year":"2025","unstructured":"Choi G, Kim YH, Shin YJ, Kim J. 411eP ETN101 suppresses tumor growth via inhibition of Wnt\/\u03b2-catenin signaling in hepatocellular carcinoma models. Ann Oncol. 2025;36:S1914. https:\/\/doi.org\/10.1016\/j.annonc.2025.10.237.","journal-title":"Ann Oncol"}],"container-title":["Current Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-026-01792-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11912-026-01792-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-026-01792-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T20:01:51Z","timestamp":1779480111000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11912-026-01792-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,22]]},"references-count":214,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1792"],"URL":"https:\/\/doi.org\/10.1007\/s11912-026-01792-5","relation":{},"ISSN":["1534-6269"],"issn-type":[{"value":"1534-6269","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,22]]},"assertion":[{"value":"22 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"57"}}